Department of Pathophysiology, Internal Medicine, Ankara University Medical School, Ankara, Turkey; Interdisciplinary Food, Metabolism and Clinical Nutrition Department, Institute of Health Sciences, Ankara University, Ankara, Turkey.
Department of Obstetrics and Gynecology, Turkish Ministry of Health Ankara City Hospital, Ankara, Turkey.
Cytokine. 2022 Jan;149:155751. doi: 10.1016/j.cyto.2021.155751. Epub 2021 Oct 30.
New biomarkers for diagnosis and monitoring the COVID-19 disease are the most important topics to be studied recently. We aimed to investigate the association between midkine levels and disease severity in pregnant women with COVID-19.
Totally 186 pregnant women were participated in this study. 96 of them were healthy pregnant women, 90 of them were pregnant women with COVID19. Pregnant women were evaluated according to their trimesters. Serum midkine level, biochemical profile clinical and disease severity outcomes of pregnant women were obtained.
Our results showed that pregnant women with COVID19 have significantly increased serum midkine level compared to healthy pregnant women (1.801 ± 0.977 vs 0.815 ± 0.294 ng/dL). According to the data among each trimester, it was shown that there were significant increase in serum midkine level during all pregnancy trimesters (1st trimester Control Group: 0.714 ± 0.148, COVID-19 group 1.623 ± 0.824, p < 0.0001; 2nd trimester Control Group: 0.731 ± 0.261, COVID-19 group 2.059 ± 1.146, p < 0.0001; 3rd trimester Control Group: 1.0 ± 0.35, COVID-19 group 1.723 ± 0.907, p = 0.001). Serum midkine levels were significantly different between disease severity subgroups of pregnant women with COVID19; moderate and severe/critic groups had significantly higher serum midkine level than mild group. There was also significant correlation between serum midkine level and severity status (p:0.0001, r: 0.468). The most striking results of serum midkine levels were corelation between length of hospitalization (p: 0.01, r: 0.430) and O saturation (p < 0.0001, r: -0.521). ROC curve analysis showed that serum midkine level might be a tool for predicting COVID-19 in pregnant women with COVID-19 (AUC: 0.912, 95% CI: [0.871, 0.952], p < 0.0001) CONCLUSION: Our data showed that there is an obvious relation between COVID19 progression and serum midkine level for the first time which might be used for monitoring the disease process.
新型生物标志物可用于诊断和监测 COVID-19 疾病，这是最近研究的最重要课题。本研究旨在探讨中期因子水平与 COVID-19 孕妇疾病严重程度的关系。
共纳入 186 例孕妇，其中 96 例为健康孕妇，90 例为 COVID-19 孕妇。根据孕期评估孕妇，获得孕妇的血清中期因子水平、生化特征、临床和疾病严重程度结果。
与健康孕妇相比，COVID-19 孕妇的血清中期因子水平显著升高（1.801 ± 0.977 比 0.815 ± 0.294 ng/dL）。根据各孕期的数据，所有孕期的血清中期因子水平均显著升高（1 期对照组：0.714 ± 0.148，COVID-19 组 1.623 ± 0.824，p < 0.0001；2 期对照组：0.731 ± 0.261，COVID-19 组 2.059 ± 1.146，p < 0.0001；3 期对照组：1.0 ± 0.35，COVID-19 组 1.723 ± 0.907，p = 0.001）。COVID-19 孕妇疾病严重程度亚组间血清中期因子水平存在显著差异；中重度/危重组血清中期因子水平显著高于轻度组。血清中期因子水平与严重程度呈显著正相关（p：0.0001，r：0.468）。血清中期因子水平与住院时间（p：0.01，r：0.430）和氧饱和度（p < 0.0001，r：-0.521）显著相关，结果最为显著。ROC 曲线分析表明，血清中期因子水平可能是预测 COVID-19 孕妇 COVID-19 的一种工具（AUC：0.912，95%CI：[0.871，0.952]，p < 0.0001）。
本研究首次表明 COVID-19 进展与血清中期因子水平之间存在明显关系，可用于监测疾病过程。
